There are 16 resources available
Welcome and introduction
Presenter: Solange Peters
Session: Pfizer Oncology - Shaping the future of ALK+ NSCLC: What’s the next leap forward?
Resources:
Webcast
Evolution of the 1L ALK+ NSCLC treatment landscape
Presenter: Giulia Pasello
Session: Pfizer Oncology - Shaping the future of ALK+ NSCLC: What’s the next leap forward?
Resources:
Webcast
Optimising patient outcomes
Presenter: Jessica Lin
Session: Pfizer Oncology - Shaping the future of ALK+ NSCLC: What’s the next leap forward?
Resources:
Webcast
Balancing efficacy with tolerability and quality of life
Presenter: Solange Peters
Session: Pfizer Oncology - Shaping the future of ALK+ NSCLC: What’s the next leap forward?
Resources:
Webcast
Pushing boundaries for the next leap forward in ALK+ NSCLC
Presenter: Solange Peters
Session: Pfizer Oncology - Shaping the future of ALK+ NSCLC: What’s the next leap forward?
Resources:
Webcast
Meeting close
Presenter: Solange Peters
Session: Pfizer Oncology - Shaping the future of ALK+ NSCLC: What’s the next leap forward?
Resources:
Webcast
New actionable targets, more potential treatment options
Presenter: Enriqueta Felip
Session: Amgen - Advancing therapeutic strategies in lung cancer care
Resources:
Webcast
Considerations for immunotherapy in 1L advanced NSCLC
Presenter: Solange Peters
Session: Regeneron - Current approaches and future strategies in non-oncogene driven advanced NSCLC
Resources:
Webcast
KRASG12C inhibitors: clinical and real-world outcomes in advanced NSCLC
Presenter: Nicolas Girard
Session: Amgen - Advancing therapeutic strategies in lung cancer care
Resources:
Webcast
Monotherapy vs. combination therapy treatment considerations
Presenter: Marina Garassino
Session: Regeneron - Current approaches and future strategies in non-oncogene driven advanced NSCLC
Resources:
Webcast